BARCELONA (Reuters) - An experimental cholesterol-lowering drug from Sanofi and Regeneron Pharmaceuticals roughly halved the number of heart attacks and strokes in a clinical trial, researchers reported on Sunday. The result is not conclusive, because the analysis was done retrospectively,…
Source: Early data suggest Sanofi, Regeneron drug may halve heart risk
Sunday, August 31, 2014
Early data suggest Sanofi, Regeneron drug may halve heart risk
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment